HB Wealth Management LLC Cuts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

HB Wealth Management LLC reduced its stake in Johnson & Johnson (NYSE:JNJ) by 0.2% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 193,270 shares of the company’s stock after selling 301 shares during the quarter. HB Wealth Management LLC’s holdings in Johnson & Johnson were worth $28,248,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of JNJ. Miller Howard Investments Inc. NY raised its holdings in shares of Johnson & Johnson by 6.0% during the 2nd quarter. Miller Howard Investments Inc. NY now owns 470,486 shares of the company’s stock valued at $68,766,000 after buying an additional 26,432 shares in the last quarter. Trajan Wealth LLC raised its stake in shares of Johnson & Johnson by 16.3% during the second quarter. Trajan Wealth LLC now owns 29,651 shares of the company’s stock worth $4,334,000 after acquiring an additional 4,159 shares in the last quarter. Beacon Financial Advisory LLC lifted its holdings in shares of Johnson & Johnson by 282.4% in the 2nd quarter. Beacon Financial Advisory LLC now owns 8,322 shares of the company’s stock worth $1,216,000 after acquiring an additional 6,146 shares during the last quarter. Aletheian Wealth Advisors LLC boosted its stake in shares of Johnson & Johnson by 3.5% in the 2nd quarter. Aletheian Wealth Advisors LLC now owns 7,458 shares of the company’s stock valued at $1,090,000 after purchasing an additional 250 shares in the last quarter. Finally, Briaud Financial Planning Inc grew its holdings in shares of Johnson & Johnson by 9.4% during the 2nd quarter. Briaud Financial Planning Inc now owns 1,153 shares of the company’s stock valued at $168,000 after purchasing an additional 99 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Up 0.2 %

Shares of NYSE JNJ opened at $164.23 on Friday. The firm has a fifty day simple moving average of $155.01 and a two-hundred day simple moving average of $153.38. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $165.83. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The firm has a market capitalization of $395.25 billion, a PE ratio of 10.24, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. Johnson & Johnson’s revenue was up 4.3% on a year-over-year basis. During the same period in the prior year, the firm earned $2.80 earnings per share. Equities analysts expect that Johnson & Johnson will post 10.07 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Tuesday, August 27th will be given a dividend of $1.24 per share. The ex-dividend date is Tuesday, August 27th. This represents a $4.96 annualized dividend and a dividend yield of 3.02%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent research reports. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 16th. Daiwa Capital Markets lowered Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Morgan Stanley raised their price target on Johnson & Johnson from $167.00 to $169.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 18th. TD Cowen lowered their price objective on Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Finally, The Goldman Sachs Group dropped their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research note on Friday, July 19th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $173.21.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.